Open-label, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients With High Risk Diffuse Large B Cell Lymphoma
Latest Information Update: 05 Oct 2022
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms Borma
- 21 Oct 2020 Planned End Date changed from 30 Oct 2018 to 30 Oct 2021.
- 21 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2018 Planned End Date changed from 1 Dec 2018 to 30 Oct 2018.